1. Home
  2. EXAS vs HSIC Comparison

EXAS vs HSIC Comparison

Compare EXAS & HSIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Exact Sciences Corporation

EXAS

Exact Sciences Corporation

HOLD

Current Price

$101.56

Market Cap

19.3B

Sector

Health Care

ML Signal

HOLD

Logo Henry Schein Inc.

HSIC

Henry Schein Inc.

HOLD

Current Price

$76.05

Market Cap

8.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EXAS
HSIC
Founded
1995
1932
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.3B
8.8B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
EXAS
HSIC
Price
$101.56
$76.05
Analyst Decision
Buy
Buy
Analyst Count
20
14
Target Price
$77.94
$76.50
AVG Volume (30 Days)
5.2M
1.2M
Earning Date
11-03-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.70
EPS
N/A
3.17
Revenue
$3,082,033,000.00
$12,938,000,000.00
Revenue This Year
$19.40
$5.35
Revenue Next Year
$13.51
$3.34
P/E Ratio
N/A
$24.04
Revenue Growth
14.47
3.51
52 Week Low
$38.81
$60.56
52 Week High
$102.66
$82.49

Technical Indicators

Market Signals
Indicator
EXAS
HSIC
Relative Strength Index (RSI) 85.02 58.78
Support Level $101.45 $76.27
Resistance Level $101.88 $78.10
Average True Range (ATR) 0.36 1.28
MACD -1.35 -0.21
Stochastic Oscillator 61.00 64.19

Price Performance

Historical Comparison
EXAS
HSIC

About EXAS Exact Sciences Corporation

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

About HSIC Henry Schein Inc.

Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology. It generates the majority of its revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.

Share on Social Networks: